Pharma BD Deal Intelligence
The thesis fully played out: UCB's $48/share, ~$2.3B buy of Ra Pharmaceuticals bet on zilucoplan in Phase 3 for generalized myasthenia gravis, and it delivered — FDA approval as ZILBRYSQ landed October 17, 2023, the only once-daily, self-administered option in the class.
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →UCB paid $48/share (93% premium) for Ra Pharma to bolt zilucoplan onto rozanolixizumab in gMG; Stifel modeled close to $2B peak sales and Jefferies over…
UCB frames the acquisition of Ra Pharmaceuticals and lead asset zilucoplan as joining forces to improve treatment options for people living with myasthenia…
CEO Jean-Christophe Tellier: 'This acquisition is a key part of this progress and an excellent strategic fit with UCB's strategy,' on completing the Ra…
Source summaries from our enrichment pipeline; follow links for originals.
All 9 sources with sentiment breakdown →
UCB acquired Ra Pharmaceuticals for $48/share in cash, a transaction valued at approximately $2.3 billion (EUR2.1 billion), announced October 10, 2019 and completed April 2, 2020. The lead asset, zilucoplan, is a once-daily subcutaneous, targeted peptide inhibitor of complement component 5 (C5), in pivotal Phase 3 (RAISE study) for generalized myasthenia gravis (gMG) at the time of the deal. The thesis fully played out: on October 17, 2023 the FDA approved zilucoplan as ZILBRYSQ for the treatment of adults with anti-acetylcholine receptor (AChR) antibody-positive gMG -- the only once-daily, self-administered gMG-targeted therapy -- and UCB launched it commercially in the U.S.
Assessment window: 5yr post-close.
$3.9B Soliris global revenue 1H 2019 annualized (gMG + PNH + aHUS)
Generalized myasthenia gravis (gMG) is a rare autoimmune neuromuscular disorder in which autoantibodies (most commonly anti-AChR) disrupt neuromuscular transmission, causing fluctuating, fatigable weakness of ocular, bulbar, limb, and respiratory muscles. It is treatable but not curable; refractory patients face high morbidity and mortality from myasthenic crises.
In 2019 the gMG treatment paradigm was shifting from chronic immunosuppression (steroids, azathioprine, mycophenolate, IVIG, plasmapheresis) toward targeted biologics. Alexion's Soliris (eculizumab, IV C5 inhibitor) had locked in ~1,200 US gMG patients and was the only FDA-approved targeted agent for AChR-Ab positive refractory gMG; its successor Ultomiris (ravulizumab, longer-acting C5) was poised to expand the franchise. Argenx's efgartigimod (FcRn antagonist, later approved as Vyvgart 2021) and Catalyst's Firdapse (3,4-DAP for LEMS — adjacent neuromuscular) were advancing. UCB itself was running rozanolixizumab (FcRn) in Phase 3, and acquiring Ra gave it zilucoplan — a once-daily subcutaneous self-injected C5 peptide — pairing two complementary mechanisms (FcRn + C5) inside one pipeline. The strategic logic: own both major non-IST mechanisms in gMG to capture switching, sequencing, and combination dynamics, while extending zilucoplan's optionality into IMNM, ALS (Healey platform), and other complement-driven rare diseases. Stifel modeled ~$2B peak sales and Jefferies >$1B, consistent with the 93% premium UCB paid. Both UCB assets ultimately reached approval (Vyvgart competed but UCB's Rystiggo and Zilbrysq launched 2023).
The FDA approved zilucoplan (brand ZILBRYSQ) on October 17, 2023 for the treatment of adults with anti-AChR antibody-positive generalized myasthenia gravis, based on the pivotal Phase 3 RAISE study. ZILBRYSQ is a once-daily subcutaneous, self-administered peptide C5 inhibitor -- validating UCB's 2019 acquisition rationale for the Ra Pharma lead asset.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| UCB S.A. / Ra Pharmaceuticals, Inc. (this deal) | 2019 | $2.1B | — |
| UCB S.A. / Candid Therapeutics, Inc. | 2026 | $2.2B | — |
| UCB S.A. / Zogenix Inc. | 2022 | $1.9B | — |
| UCB S.A. / Neurona Therapeutics, Inc. | 2026 | $1.1B | — |
| UCB S.A. / Antengene Corporation Limited | 2026 | $1.2B | — |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| PerkinElmer, Inc. / EUROIMMUN Medizinische Labordiagnostika AG | 2017 | $1.3B | 88 |
← Browse all deals · How we score deals
More: 2019 deals · UCB S.A. deals · Immunology deals